Piuhola Jarkko, Tenhunen Olli, Kerkelä Risto
Duodecim. 2015;131(5):441-7.
With the development of new protein kinases, antibodies, immunomodulators and hormonal treatments, significant progress has taken place in the last few years in the pharmacological treatment of cancers. At the same time, old cytotoxic drugs still remain in use. In regard to the heart, anthracyclines are the most problematic cytotoxic drugs, as they may cause cardiac insufficiency that is manifested only years after the treatment. Also trastuzumab and kinase inhibitors may cause cardiac insufficiency. Fluoropyrimidines cause myocardial ischemia for some patients. Treatments targeting VEGF inhibition are frequently associated with significant elevation of blood pressure.
随着新型蛋白激酶、抗体、免疫调节剂和激素治疗方法的发展，在过去几年中癌症的药物治疗取得了重大进展。与此同时，旧的细胞毒性药物仍在使用。就心脏而言，蒽环类药物是最成问题的细胞毒性药物，因为它们可能导致心脏功能不全，而这种情况仅在治疗数年之后才会显现出来。曲妥珠单抗和激酶抑制剂也可能导致心脏功能不全。氟嘧啶会使一些患者出现心肌缺血。针对血管内皮生长因子（VEGF）抑制的治疗常常与血压显著升高有关。
